| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
MK-5108 (also known as VX-689) is a novel, specific and ATP-competitive inhibitor of Aurora A kinase with potential anticancer activity. It inhibits Aurora A kinase with an IC50 of 0.064 nM in a cell-free assay. MK-5108 also less potently inhibits other Aurora kinases, including Aurora B kinase (IC50 = 14 nM) and Aurora C kinase (IC50 = 12 nM). MK-5108 has been found to exhibit antitumor activity in a wide range of cancer types, including breast, cervix, colorectal, ovary and pancreas neoplasms.
| ln Vitro |
MK-5108 has an IC50 value of 0.064 nM and inhibits Aurora-A activity in an ATP-competitive manner. Compared to the other family circuits, Aurora-B (220-fold) and Aurora-C (190-fold), it demonstrated stronger switching. The selectivity of MK-5108 towards Aurora-A is also interfered with by other proteins. 14 cell lines are inhibited in growth by MK-5108, with IC50 values ranging from 0.16 to 6.4 μM [1].
|
||
|---|---|---|---|
| ln Vivo |
In the HCT116 tumor model, MK-5108 therapy at 15 and 30 mg/kg significantly inhibited tumor growth. MK-5108 caused little weight loss and was well tolerated at both dosages. Significant anti-tumor efficacy was also demonstrated by MK-5108 in nude mice with SW48 tumors. Tumor growth inhibition was dose-dependent and produced %T/C of 35% and 7% on day 10 and 58% and 32% on day 27 at 15 and 45 mg/kg of MK-5108, respectively. In naked mice, MK-5108 was well tolerated, causing little weight loss and only mild effects on blood cells [1].
|
||
| Animal Protocol |
|
||
| References |
[1]. Shimomura T, et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther. 2010 Jan;9(1):157-66
|
| Molecular Formula |
C22H21CLFN3O3S
|
|
|---|---|---|
| Molecular Weight |
461.94
|
|
| CAS # |
1010085-13-8
|
|
| Related CAS # |
|
|
| SMILES |
O=C([C@@]1(CC2=NC(NC3=NC=CS3)=CC=C2)CC[C@H](OC4=CC=CC(Cl)=C4F)CC1)O
|
|
| InChi Key |
LCVIRAZGMYMNNT-VVONHTQRSA-N
|
|
| InChi Code |
InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)/t15-,22-
|
|
| Chemical Name |
(1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid
|
|
| Synonyms |
VX-689; VX689; VX 689; MK5108; MK-5108; MK 5108; VX-689
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1648 mL | 10.8239 mL | 21.6478 mL | |
| 5 mM | 0.4330 mL | 2.1648 mL | 4.3296 mL | |
| 10 mM | 0.2165 mL | 1.0824 mL | 2.1648 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00543387 | Completed Has Results | Drug: MK-5108 Drug: docetaxel |
Cancer, Neoplasms, Tumors | Merck Sharp & Dohme LLC | March 27, 2008 | Phase 1 |
MK-5108 is a highly potent and selective inhibitor of Aurora-A kinase.Mol Cancer Ther. 2010 Jan;9(1):157-66. |
MK-5108 inhibits the proliferation of cultured human cell lines and growth of xenograft tumors.A,SCID mice bearing HCT116 tumors were treated orally twice daily for 12 consecutive days with either vehicle control (•) or MK-5108 at 15 mg/kg (▴) or 30 mg/kg ( |
MK-5108 induces the accumulation of mitotic cells in HeLa-luc tumors and skin hair bulbs.Mol Cancer Ther. 2010 Jan;9(1):157-66. |
MK-5108 induces accumulation of mitotic cells in HeLa-S3 cells. HeLa-S3 cells were released from the G1-S block. MK-5108 (A) or MLN8054 (B) was added at 4 h and the percentage of pHH3-positive cells was determined at 18 h by immunofluorescent analysis as described in Materials and Methods.C,DNA profiles of asynchronously cultured HeLa-S3 cells treated by MK-5108 or MLN8054 for 24 h were evaluated by flow cytometry.Mol Cancer Ther. 2010 Jan;9(1):157-66. |
MK-5108 enhances the effects of docetaxel on the inhibition of cell proliferation and induction of cell death.Mol Cancer Ther. 2010 Jan;9(1):157-66. |
MK-5108 enhances the antitumor activity of docetaxel without affecting toxicity.AtoD,nude rats bearing dual HeLa-luc and ES-2 xenograft tumors in each flank were treated with vehicle control (○), docetaxel (•), MK-5108 (▵), and docetaxel and MK-5108 in combination (▴;n= 5 rats per group). Docetaxel was injected i.v. at 7.5 mg/kg.Mol Cancer Ther. 2010 Jan;9(1):157-66. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
;n= 5 mice per group).
